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Context: Hormonal treatment in transgender persons affects many components of the metabolic
syndrome (MS).
Objective: To determine the role of direct hormonal effects, changes in metabolic cytokines, and
body composition on metabolic outcomes.
Design, Setting, and Participants: 24 transwomen and 45 transmen from the European Network for
the Investigation of Gender Incongruence were investigated at baseline and after 12 months of
hormonal therapy.
Outcome Measures: Best predictors for changes in components of MS, applying least absolute
shrinkage and selection operator regression.
Results: In transwomen, a decrease in triglyceride levels was best explained by a decrease in fatmass
and an increase in fibroblast growth factor 21 (FGF-21); the decrease in total and low-density
lipoprotein cholesterol levels was principally due to a decrease in resistin. A decrease in high-density
lipoprotein cholesterol depended on an inverse association with fat mass. In contrast, in transmen,
an increase in low-density lipoprotein cholesterol was predicted by a decrease in FGF-21 and an
increase in the waist/hip ratio; a decrease in the high-density lipoprotein/total cholesterol ratio
depended on a decline in adiponectin levels. In transwomen, worsened insulin resistance and
increased early insulin response seemed to be due to a direct treatment effect; however,
improvements in hepatic insulin sensitivity in transmen were best predicted by a positive
association with chemerin, resistin, and FGF-21 and were inversely related to changes in the
waist/hip ratio and leptin and adipocyte fatty acid-binding protein levels.
Conclusions: The effects of hormonal therapy on different components of the MS are sex-specific
and involve a complex interplay of direct hormonal effects, changes in body composition, and
metabolic cytokine secretion. (J Clin Endocrinol Metab 103: 790–802, 2018)
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Transgender individuals are characterized by an in-congruence between gender identity and external
sexual anatomy at birth. An etiological reason for this
phenomenon has yet to be identified, although psycho-
logical and biological factors have been implicated (1,
2). To mitigate the feeling of gender dysphoria, inter-
ventions such as gender-affirming hormonal therapy
(GAHT) and gender-affirming surgery are often applied
during the medical care of transgender persons.
GAHT in transgender persons has enabled, to some
extent, investigation of the physiological role of sex
steroids, although these are only partially uncoupled
from other sex-specific factors that could have an in-
fluence. Regarding the metabolism, it is already known
that GAHT results in impressive changes in physical
appearance toward the target sex (3, 4). For example,
long-term testosterone treatment in transmen increases
the visceral fat mass and decreases the subcutaneous fat
mass (3). In addition, it has been repeatedly shown that
the classic cardiovascular risk factors belonging to the
metabolic syndrome (MS), such as lipid levels, approach
those of the target sex. High-density lipoprotein (HDL)
levels and, in particular, theHDL/low-density lipoprotein
(LDL) ratio usually increase in transwomen and decrease
in transmen (5–9). In addition, distinct changes occur in
the glucose metabolism after GAHT in transgender in-
dividuals (6).
Previously, it was suggested that cytokines derived
from adipose tissue (i.e., adipokines) and/or from the liver
(i.e., hepatokines) influence facets of the MS. Thus,
dysregulation of these cytokines, including adiponectin,
leptin, fibroblast growth factor 21 (FGF-21), and adi-
pocyte fatty acid-binding protein (AFABP), is associated
with insulin resistance and dyslipidemia [reviewed by
Fasshauer and Blu¨her (10)]. Many of these cytokines
exhibit sexual dimorphism, and it has been demon-
strated previously in small cohorts that GAHT can affect
circulating levels of cytokines, such as adiponectin and
leptin (11, 12).
However, the underlying mechanisms and conse-
quences are poorly understood. Thus, the extent to which
changes in metabolic cytokine concentrations contribute
to the observed effects on components of the MS during
GAHT, in addition to subsequent changes in body
composition (e.g., fat mass) and the direct effects of al-
tered sex steroids, remains unknown. Furthermore, most
studies have only investigated classical adipokines, in-
cluding leptin and adiponectin, and have yet to explore
novel adipose tissue-secreted proteins influencing aspects
of the MS.
Therefore, the present research investigated a distinct
set of novel and well-established metabolic cytokines that
exhibit sexual dimorphism (13) and are associated with
aspects of the MS within a prospective cohort of 69
transgender individuals before and 12 months after
GAHT. The aim of the present studywas to determine the
effect of these cytokines on the metabolic phenotype of
transgender individuals undergoing GAHT, in addition




The present research forms part of the European Network
for the Investigation of Gender Incongruence, a collaboration of
four major West European gender identity clinics (Amsterdam,
Ghent, Florence, and Oslo), and a study group created to
achieve greater transparency in the diagnosis and treatment of
gender dysphoria. Aspects of the study design have been pre-
viously reported (4, 14). All participants recruited for the
present study received a diagnosis and were treated at the
Department of Endocrinology, Ghent University Hospital,
Belgium, from February 2010 to March 2014. One year of
follow-up data from 57 transmen and 72 transwomen were
available during the study period. Patients were only selected for
the present analysis if they did not have dyslipidemia, diabetes
mellitus, or glucose intolerance and had not been receiving any
hormonal treatment at baseline. Twenty-one transmen were
already receiving 5 mg lynestrenol daily (Orgametril) or taking
hormonal contraceptives to stop their menstrual cycle and were
therefore not selected for the present analysis. Patients with
incomplete data on body composition at any of the relevant time
points were also excluded.
Finally, a total cohort of 69 transgender individuals was
available for the present analysis, including 45 transwomen
(male to female) and 24 transmen (female to male), who were
investigated at baseline and after 12 months of GAHT. Data on
the oral glucose tolerance test (OGTT) and the calculated in-
dexes for both time points in this sample were available for 38
transmen and 17 transwomen.
GAHTwith 1000mg of testosterone undecanoate (Nebido®;
Jenapharm, Jena, Germany), administered every 3 months,
was given to all transmen. In accordance with the Endocrine
Society Guidelines (15), the chosen hormonal treatment of
the transwomen was dependent on their age and included
50 mg of cyproterone acetate (CPA) administered once daily
(Androcur®; Bayer, Leverkusen, Germany), in addition to 2 mg
of estradiol valerate (Progynova®; Bayer) administered twice
daily. Transwomen aged.45 years received 50mg ofCPAdaily
and a transdermal 17-b-estradiol (E2) patch releasing 100 mg
every 24 hours (Dermestril®; Besins, Brussels, Belgium) (n =
17). All investigations were conducted by trained staff and
included standardized questionnaires, anthropometric param-
eters [body mass index, waist/hip ratio (WHR), and a 75-g
OGTT]. Body composition analysis was performed using dual-
energy X-ray absorptiometry using a Hologic Discovery Ma-
chine (Hologic Inc., Bedford, MA). As described previously
(16), the indexes of insulin sensitivity and b-cell function were
calculated from the fasting andOGTTmeasurements of glucose
and insulin.
The ethical review board of the Ghent University Hospital,
Belgium approved the present research, which was conducted in
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accordance with the Declaration of Helsinki. All participants
gave written informed consent before inclusion. The present
study is registered at www.ClinicalTrials.gov (ClinicalTrials.
gov identifier, NCT01072825).
Assays
For all participants, serum samples at both time points (i.e.,
baseline and 12-month follow-up point) were taken in the
morning between 8:00 and 9:00 AM after an overnight fast.
After a clotting period of 30 to 60 minutes, the serum was
centrifuged and stored at 280°C until further analysis. E2 and
testosterone were determined using liquid chromatography
tandem mass spectrometry (AB Sciex 5500 triple quadrupole
mass spectrometer; AB Sciex, Toronto, ON, Canada). Serum
adipokine concentrations were determined using commercially
available enzyme-linked immunosorbent assays in line with the
manufacturers’ instructions (adiponectin; Mediagnost, Reutlin-
gen, Germany; leptin, progranulin, chemerin, resistin, FGF-21,
and AFABP, BioVendor Inc., Brno, Czech Republic). Further
immunoassays were used to determine the levels of follicle-
stimulating hormone (FSH), luteinizing hormone (LH), and sex
hormone-binding globulin.
Routine parameters, including fasting glucose, glucose and
insulin levels during the OGTT, total cholesterol (TC), HDL
cholesterol, LDL cholesterol, and triglycerides (TGs), were
measured using standard methods in a certified laboratory
(Ghent University Hospital, Ghent, Belgium).
Statistical analysis
For statistical analysis of the anthropometric and serum
data, SPSS software, version 24.0 (IBM, Armonk, NY), and R
software, version 3.1.2 (17), were used. Data were examined
for normality using quantile-quantile plots and, if skewed,
were normalized by log transformation before further analysis.
To evaluate the effects of 12 months of GAHT on the different
outcome variables, mixed-effects models with repeated mea-
sures over time and incorporating a within participants design
were used to compare the mean changes over time between the
two groups. Most outcome parameters displayed a substantial
time 3 sex interaction; therefore, longitudinal analyses using
mixed models were performed separately for each sex. To
ascertain whether changes in metabolic cytokine data occurred
independently of the changes in body composition and dif-
ferences in age between the transwomen and transmen, fat
mass and age were used as covariates in a second mixed effects
model, again performed separately for transmen and trans-
women. In all the mixed models, participants were treated
as a random effect. In the repeated statement, an unstruc-
tured covariance structure was used. The Spearman correla-
tion was used to investigate univariate correlations between
changes inmetabolic outcomes, metabolic cytokines, and body
composition.
Finally, to determine which factors best explained any shifts
in metabolic parameters during the treatment, a variable se-
lection approach was used on a change–change model. This
initially required reducing the data to absolute changes from the
baseline values. The derived variables were then subjected to a
linear model with the change in metabolic parameters (e.g.,
cholesterol) as an outcome variable, with changes in adipokines, lean
body mass, fat mass, WHR, and age as predictor variables. Because
the mode of estradiol administration in the transwomen was
dependent on age, it was not adjusted for separately. However,
several of the predictor variables showed strong correlations,
violating the assumptions of simple linear regression. To ac-
commodate this, least absolute shrinkage and selection operator
(LASSO) regression (18) was chosen and applied. The optimal
lambda was also selected, using leave-one-out cross-validation.
Additionally, the LASSO penalizes unimportant predictors by
applying zero coefficients and hence provides a powerful
method for variable selection. Based on the selected variables,
final simplified regression models were run to obtain P values
and effect estimates. All statistical tests were performed with
a # 0.05 (two-tailed).
Results
General characteristics at baseline
At baseline, the transwomen were older (P = 0.009)
than the transmen but did not differ in terms of any
other anthropometric measure. The transmen seemed to
be more active regarding sports activity than were the
transwomen (P = 0.010), with no difference in other
indicators of physical activity found. The baseline char-
acteristics are listed in Table 1.
Adiponectin (P = 0.047), leptin (P = 0.016), resistin
(P = 0.013), and AFABP (P = 0.047) levels were lower in
the transwomen than in the transmen. No statistically
significant differences were found for either sex regarding
lipid parameters, although fasting glucose (P = 0.030)
was higher and fasting insulin levels (P = 0.001) were
lower in the transwomen. This also translated into a
higher homeostasis model assessment (HOMA) of b-cell
function (HOMA-B; P = 0.001) and lower HOMA of
insulin resistance (HOMA-IR; P = 0.001).
Longitudinal analysis
Details of the longitudinal analysis are listed in
Table 2.
Markers of the MS
Anthropometry. An increase in fat mass was found in the
transwomen (P , 0.001) and a decrease in the transmen
(P = 0.048). The lean mass increased in the transmen (P =
0.049) but remained unchanged in the transwomen. The
hip circumference increased (P = 0.049) and WHR de-
creased (P = 0.007) in the transwomen, with no change
found in the transmen. Although no substantial changes
were found regarding physical activity measures in the
transwomen, a substantial decrease regarding work and
overall physical activity occurred in the transmen.
Blood pressure. A trend was seen toward an increase
in systolic blood pressure in the transmen (P = 0.065).
However, the diastolic blood pressure remained un-
changed during the observation period for both sexes.
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Table 1. Baseline Characteristics
Characteristic
Transwomen (Male to Female) Transmen (Female to Male)
P ValueaMean 6 SE 95% CI Mean 6 SE 95% CI
Age, y 34.8 6 1.4 NA 27.5 6 1.3 NA 0.009b
Body composition
Fat mass, kg 14.6 6 1.0 12.6–16.7 19.0 6 14.2 162–21.8 0.425
Lean mass, kg 59.5 6 1.3 56.9–62.0 45.3 6 17.4 41.8–48.7 0.385
Weight, kg 74.6 6 2.1 70.3–78.9 65.0 6 2.9 59.1–70.8 0.047b
BMI, kg/m2 23.8 6 0.7 22.5–25.2 24.0 6 0.9 22.2–25.9 0.443
Waist, cmc 82.8 6 1.7 79.5–86.2 76.0 6 2.3 71.4–80.5 0.189
Hip, cmc 95.3 6 1.3 92.7–98.0 97.8 6 1.8 94.3–101.4 0.615
WHR 0.868 6 0.012 0.845–0.892 0.776 6 0.016 0.744–0.808 0.221
SBP, mm Hg 127.3 6 2.2 123.0–131.6 109.8 6 2.9 104.1–115.6 0.507
DBP, mm Hg 77.4 6 1.6 74.1–80.6 70.6 6 2.2 66.2–74.9 0.584
Adipokines
Adiponectin, mg/Lc 7517.2 6 657.1 6204.4–8830.0 10,799.4 6 940.3 8920.9–12,677.9 0.047b
Chemerin, mg/L 267.0 6 7.1 252.8–281.3 276.7 6 10.2 256.3–297.2 0.540
Resistin, mg/L 6.5 6 0.3 5.8–7.1 7.7 6 0.5 6.7–8.6 0.013b
Progranulin, mg/L 36.3 6 1.0 34.3–38.4 36.8 6 1.5 33.8–39.7 0.465
Leptin, mg/Lc 3.4 6 0.4 2.5–4.2 15.1 6 2.9 9.2–21.1 0.016b
FGF-21, ng/Lc 186.1 6 23.8 138.6–233.6 146.2 6 34.0 78.2–214.2 0.279
AFABP, mg/Lc 16.0 6 2.1 11.7–20.2 18.1 6 3.1 12.0–24.2 0.047b
Sex hormones
LH, U/Lc 10.8 6 1.2 2.9–7.7 10.8 6 12.6 8.5–15.1 0.001b
FSH, U/Lc 5.3 6 1.1 3.2–7.4 6.7 6 7.2 4.9–10.7 0.000b
E2, ng/Lc 29.7 6 6.6 16.5–42.8 123.1 6 77.8 105.2–141.1 0.003b
Testosterone, ng/dLc 504.3 6 23.6 457.3–551.3 44.2 6 42.4 20.2–108.5 , 0.001b
SHBG, nmol/Lc 39.6 6 5.1 29.3–49.6 75.5 6 45.5 61.9–89.1 0.310
Lipids
TG, mg/dLc 117.7 6 15.9 86.1–149.3 94.1 6 22.8 48.8–139.4 0.486
TC, mg/dL 195.2 6 5.8 183.7–206.7 175.4 6 8.2 158.9–191.8 0.163
HDL, mg/dL 56.5 6 2.1 52.4–60.6 59.2 6 2.9 53.3–65.0 0.579
HDL, % 30.0 6 1.4 27.3–32.7 35.3 6 2.0 31.4–39.2 0.582
LDL, mg/dLc 115.0 6 4.6 105.8–124.1 98.7 6 6.5 85.6–111.7 0.120
Physical activity
Sport 3.0 6 0.2 2.6–3.3 2.4 6 0.1 2.2–2.6 0.010b
Leisure time 2.9 6 0.2 2.6–3.2 3.1 6 0.1 2.9–3.2 0.478
Work 2.7 6 0.1 2.4–3.0 2.7 6 0.1 2.4–2.9 0.997
Total 8.6 6 0.4 7.8–9.2 8.1 6 0.2 7.7–8.6 0.303
Glucose metabolism, OGTT
Glucose 0 min, mmol/L 4.9 6 0.1 4.7–5.0 4.6 6 0.6 4.4–4.8 0.030b
Glucose 30 min, mmol/L 8.7 6 0.3 8.2–9.2 7.8 6 1.6 7.1–8.5 0.668
Glucose 60 min, mmol/L 8.6 6 0.3 7.9–9.3 7.5 6 2.5 6.6–8.5 0.816
Glucose 120 min, mmol/L 6.0 6 0.3 5.4–6.6 5.3 6 1.9 4.5–6.1 0.228
Insulin 0 min, SIc 56.7 6 5.5 45.7–67.8 79.1 6 53.2 64.3–94.0 0.001b
Insulin 30 min, SIc 452.7 6 39.6 373.6–531.8 475.0 6 276.4 365.6–584.4 0.952
Insulin 60 min, SIc 628.4 6 54.8 519.0–737.8 548.9 6 248.6 400.8–697.1 0.176
Insulin 120 min, SIc 369.1 6 40.5 288.3–449.9 512.2 6 347.8 402.8–621.6 0.126
Indexes
AUC glucosec 904.2 6 27.1 850.0–958.4 799.4 6 38.4 722.8–876.1 0.796
AUC insulinc 52,940.1 6 4019.9 44,904.0–60,976.2 50,750.9 6 5773.5 39,207.3–62,294.6 0.731
HOMA-IRc 1.7 6 0.2 1.3–2.1 2.4 6 0.3 1.8–3.0 0.001b
HOMA-Bc 212.3 6 25.0 162.2–262.4 170.9 6 37.7 95.4–246.4 0.001b
HOMA-SECc 152.8 6 15.7 121.3–184.2 236.7 6 22.0 192.7–280.7 0.675
Insulinogenic indexc 145.6 6 26.5 92.6–198.7 108.0 6 40.1 27.5–188.4 0.297
Stumvoll MCRc 7.8 6 0.3 7.1–8.5 7.3 6 0.5 6.4–8.3 0.128
Abbreviations: CI, confidence interval; DBP, diastolic blood pressure; HOMA-SEC, HOMA of first-phase insulin secretion; NA, not applicable; SBP, systolic
blood pressure; SHBG, sex hormone-binding globulin; SI, International System of Units.
aStudent’s t test.
bStatistically significant.
cVariables normalized by log-transformation before analysis.
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Lipids. In the transwomen, the TG levels (P = 0.004) and
TC levels (P, 0.001) decreased, although they remained
stable in the transmen. A statistically significant decrease
was found in HDL in both sexes (P , 0.001 for both).
However, although the HDL/TC ratio (HDL%) in the
transwomen remained unchanged, it decreased in the
Table 2. Longitudinal Analysis
Variable
Transwomen (Male to Female) at 12 mo
Mean 6SE 95% CI
Crude Analysisa Adjusteda,b
DirectioncF P Value F P Value
Body composition
Fat mass, kg 18 6 1.1 15.8 to 20.2 19.675 , 0.001d ↑
Lean mass, kg 57.5 6 1.8 53.9 to 61.2 23.739 , 0.001d ↓
BMI, kg/m2 24.2 6 0.7 22.8 to 25.6 0.217 0.643
Waist, cm 82.2 6 1.9 78.7 to 86.2 0.163 0.688
Hip, cm 98.7 6 1.4 95.8 to 101.6 4.090 0.049d ↑
WHR 0.827 6 0.01 0.8 to 0.853 7.931 0.007d ↓
SBP, mm Hg 120.6 6 3 114.6 to 126.6 2.768 0.103
DBP, mm Hg 75.7 6 1.6 72.6 to 79.1 0.591 0.446
Adipokines
Adiponectin, mg/L 8604.9 6 547 7513 to 9697 4.307 0.044d 4.294 0.044d ↑
Chemerin, mg/L 247.9 6 11 225.9 to 269.9 4.642 0.037d 4.642 0.037d ↓
Resistin, mg/L 6.5 6 0.3 5.9 to 7.2 0.083 0.774 0.083 0.774
Progranulin, mg/L 33.4 6 1.4 30.6 to 36.3 6.089 0.017d 4.297 0.053 ↓
Leptin, mg/L 9.3 6 1.2 6.9 to 11.6 6.089 , 0.001d 113.1 , 0.001d ↑
FGF-21, ng/L 137.3 6 19.4 98.7 to 176 113.103 0.010d 7.142 0.010d ↓
AFABP, mg/L 14.8 6 1.7 11.3 to 18.2 7.142 0.631 0.234 0.631
Sex hormones
LH, U/L 1.7 6 2.1 22.4 to 5.9 0.234 , 0.001d ↓
FSH, U/L 1.6 6 2 22.4 to 5.7 114.979 , 0.001d ↓
E2, ng/L 108.9 6 16.2 76.6 to 141.1 130.199 , 0.001d ↑
Testosterone, ng/dL 53.8 6 23.5 7.3 to 100.9 59.570 , 0.001d ↓
SHBG, nmol/L 40.7 6 2.4 36 to 45.4 0.801 0.376
Lipids
TG, mg/dL 82.5 6 17.5 48.2 to 116.7 9.143 0.004d ↓
TC, mg/dL 164.6 6 5.2 154.3 to 174.9 42.200 , 0.001d ↓
HDL, mg/dL 48.2 6 1.6 45 to 51.3 21.809 , 0.001d ↓
HDL, % 30.4 6 1.2 28 to 32.7 0.336 0.565
LDL, mg/dL 99.3 6 4.5 90.4 to 108.2 27.532 , 0.001d ↓
Physical activity
Sport 2.9 6 0.2 2.5 to 3.2 2.9 0.618
Leisure 3.0 6 0.2 2.7 to 3.3 3.0 0.480
Work 2.8 6 0.1 2.5 to 3.0 2.8 0.538
Total 8.7 6 0.4 7.9 to 9.4 8.7 0.755
Glucose metabolisme
Glucose, mmol/L
0 min 4.8 6 0.1 4.6 to 5 1.350 0.252
30 min 8 6 0.3 7.3 to 8.7 3.509 0.068
60 min 8 6 0.3 7.3 to 8.6 3.006 0.091
120 min 6.2 6 0.3 5.7 to 6.8 0.438 0.511
Insulin, SI
0 min 78.9 6 5.2 68.4 to 89.3 19.588 , 0.001d ↑
30 min 469 6 39.6 397.4 to 556 0.528 0.472
60 min 642.6 6 53.8 529.8 to 744.9 0.421 0.520
120 min 553.6 6 52.2 448.7 to 657.7 17.342 , 0.001d ↑
Indexese
AUC glucose 851.4 6 26.7 797.9 to 904.8 2.568 0.117
AUC insulin 59,956 6 4753 50,438 to 69,474 3.016 0.090
HOMA-IR 2.5 6 0.2 2 to 2.9 12.739 0.001d ↑
HOMA-B 132.1 6 13.6 104.9 to 159.3 22.675 , 0.001d ↓
HOMA-SEC 245.5 6 28.8 187.9 to 303.1 22.675 , 0.001d ↑
Insulinogenic index 119.8 6 14.2 91.4 to 148.2 1.902 0.175
Stumvoll MCR 6.5 6 0.3 5.8 to 7.2 5.172 0.028d ↓
(Continued)
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Table 2. Continued
Variable
Transmen (Female to Male) at 12 mo
Mean 6 SE 95% CI
Crude Analysisa Adjusteda,b
DirectioncF P Value F P Value
Body composition
Fat mass, kg 16.4 6 15.4 14.3 to 20.4 4.380 0.048d ↓
Lean mass, kg 60.3 6 25.5 56.5 to 66.6 26.641 , 0.001d ↑
BMI, kg/m2 25.1 6 1 23.1 to 27 4.352 0.048d
Waist, cm 77.8 6 2.6 72.5 to 82.9 1.990 0.171
Hip, cm 97.5 6 2 93.9 to 101.7 0.009 0.925
WHR 0.795 6 0.018 0.76 to 0.831 3.025 0.095
SBP, mm Hg 117 6 4.4 108.3 to 125.7 3.769 0.065
DBP, mm Hg 74 6 2.4 69.3 to 78.7 1.995 0.172
Adipokines
Adiponectin, mg/L 6142.5 6 782.1 4580 to 7705 40.332 , 0.001d 35.735 , 0.001d ↓
Chemerin, mg/L 238.2 6 15.7 206.8 to 269.7 6.181 0.020d 6.627 0.014d ↓
Resistin, mg/L 7.8 6 0.5 6.9 to 8.8 0.168 0.686 0.012 0.915
Progranulin, mg/L 34.9 6 1 32.9 to 36.9 13.910 0.001d 12.017 0.002d ↓
Leptin, mg/L 6.5 6 1.3 3.8 to 9.2 63.498 , 0.001d 76.419 , 0.001d ↓
FGF-21, ng/L 176.8 6 27.7 121.4 to 232.1 0.164 0.689 0.302 0.588
AFABP, mg/L 19.6 6 2.5 14.6 to 24.5 0.291 0.595 0.277 0.604
Sex hormones
LH, U/L 11 6 2.9 5.3 to 16.7 10.112 0.004d ↓
FSH, U/L 11.7 6 2.8 6.1 to 17.2 1.492 0.235
E2, ng/L 108.9 6 22.7 6.3 to 96.5 19.864 , 0.001d ↓
Testosterone, ng/dL 656.6 6 32.4 592 to 721.5 380.128 , 0.001d ↑
SHBG, nmol/L 40.7 6 5.1 29.3 to 49.6 58.930 , 0.001d ↓
Lipids
TG, mg/dL 90.3 6 12 66.9 to 113.8 0.422 0.522
TC, mg/dL 177.3 6 7.5 162.4 to 192.3 0.129 0.723
HDL, mg/dL 51 6 2.3 46.4 to 55.6 20.579 , 0.001d ↓
HDL, % 29.8 6 1.7 26.4 to 33.2 30.172 , 0.001d ↓
LDL, mg/dL 109.5 6 6.4 96.8 to 122.3 7.871 0.01d ↑
Physical activity
Sport 2.4 6 0.1 2.1 to 2.6 0.358 0.553
Leisure 3.0 6 0.1 2.8 to 3.1 1.236 0.273
Work 2.5 6 0.1 2.2 to 2.7 5.653 0.022d ↓
Total 7.8 6 0.2 7.3 to 8.2 5.521 0.022d ↓
Glucose metabolisme
Glucose, mmol/L
0 min 4.4 6 0.1 4.2 to 4.7 1.258 0.273
30 min 8.3 6 8.3 7.4 to 9.2 0.689 0.415
60 min 8.1 6 0.5 7.2 to 9.1 0.683 0.417
120 min 5.7 6 0.4 4.9 to 6.4 0.285 0.599
Insulin, SI
0 min 51.9 6 7.5 39.1 to 69.1 9.994 0.005d ↓
30 min 469.6 6 55.8 369.9 to 593 0.045 0.834
60 min 735.1 6 76.9 596.8 to 903.8 9.896 0.005d ↓
120 min 463.3 6 72.6 357 to 647.5 0.151 0.702
Indexese
AUC glucose 885.7 6 37.3 811 to 960.4 0.628 0.433
AUC insulin 59,275.5 6 7054.2 45,155.5 to 73,395.6 1.887 0.187
HOMA-IR 1.5 6 0.3 0.8 to 2.2 10.382 0.004d ↓
HOMA-B 132.1 6 13.6 104.9 to 159.3 0.744 0.399
HOMA-SEC 197.7 6 43.4 187.9 to 303.1 0.744 0.399
Insulinogenic index 133.6 6 20.4 92.9 to 174.3 3.063 0.096
Stumvoll MCR 7.3 6 0.5 6.2 to 8.3 0.006 0.944
Abbreviations: CI, confidence interval; DBP, diastolic blood pressure; HOMA-SEC, HOMA of first-phase insulin secretion; SBP, systolic blood pressure;
SHBG, sex hormone-binding globulin; SI, International System of Units.
aMixed model analysis.
bAdjusted for age and fat mass.
cArrows indicate direction of statistically significant changes between baseline and 12 mo.
dStatistically significant.
eData on OGTT and calculated indexes for both time points were available for 17 transmen and 38 transwomen.
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transmen (P , 0.001). Furthermore, LDL cholesterol
decreased in the transwomen (P , 0.001) and increased
in the transmen (P = 0.010).
Glucose metabolism. An increase occurred in the fasting
insulin levels (P , 0.001) in the transwomen, with a
decrease in the transmen (P = 0.005). In contrast, neither
fasting glucose nor the glucose and insulin levels during
OGTT [area under the curve (AUC)] were affected by
12 months of GAHT for either sex. In transwomen,
HOMA-IR (P = 0.001) and HOMA of first-phase insulin
secretion (P , 0.001) increased. In contrast, a decrease
occurred in the Stumvoll metabolic clearance rate (MCR;
P = 0.028) and the HOMA-B (P , 0.001). In transmen,
the HOMA-IR decreased (P = 0.004).
Sex hormones
A decrease occurred in LH levels in both sexes (P ,
0.001 for transwomen; P = 0.004 for transmen), and FSH
decreased in transwomen (P , 0.001) but not in trans-
men. As expected, an increase in E2 occurred in the
transwomen and a decrease in the transmen (P, 0.001).
In contrast, a decrease in testosterone occurred in the
transwomen, with an increase in the transmen (P ,
0.001). Also, a decrease occurred in sex hormone-binding
globulin in the transmen (P, 0.001), with no statistically
significant change in the transwomen (P = 0.376).
Metabolic cytokines
The adiponectin levels increased in the transwomen (P
= 0.044) but strongly decreased in the transmen (P ,
0.001). The chemerin levels decreased in both sexes (P =
0.037 for transwomen, P = 0.020 for transmen), but no
change was found in resistin levels in either sex, with
resistin levels greater in the transmen at both time points.
Circulating progranulin decreased in transwomen (P =
0.017) and in transmen (P = 0.001). The FGF-21 serum
concentration decreased in the transwomen (P = 0.010)
but remained unchanged in the transmen. All statistically
significant changes, except for the decrease in pro-
granulin levels in transwomen, remained statistically
significant after adjusting for age and fat mass. No rel-
evant change was observable for AFABP (Fig. 1). Uni-
variate correlations between the changes in metabolic
outcome parameters and changes in metabolic cytokines
and body composition are shown in Fig. 2.
Figure 1. Changes in metabolic cytokines. Adiponectin levels increased in transwomen (P = 0.044) but strongly decreased in transmen (P ,
0.001). A decrease was found in chemerin levels in both sexes (P = 0.037 for transwomen, P = 0.020 for transmen), with no change in resistin
levels in either sex, with resistin levels higher in transmen at both time points. Circulating progranulin decreased in transwomen (P = 0.017)
and in transmen (P = 0.001). FGF-21 serum concentrations decreased in transwomen (P = 0.010) but remained unchanged in transmen. All
statistically significant changes, except for the decrease in progranulin levels in transwomen, remained statistically significant after adjusting for
age and fat mass. No substantial change was observable for AFABP. Data presented as mean 6 standard error of the mean.
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Multivariate analysis of outcomevariables by LASSO
As depicted in Fig. 3, most outcome variables were, as
expected, strongly affected by their baseline values. The b
and P values are listed in Supplement Tables 1 to 4.
Lipid parameters
In the adjusted models, in the transwomen, a decrease
in TGs was associated with a decrease in fat mass (P =
0.01) and an increase in FGF-21 levels (P, 0.001), such
that a decrease of 1 kg in fat body mass was associated
with a decrease in TG levels of 4mg/dL and an increase in
1 U of FGF-21 with a decrease of 0.1 mg/dL (Supplement
Table 1).
In contrast, in the transmen, no substantial changes
were seen in TGs during the observation period; however,
a positive association was seen with changes in FGF-21
levels. Our model showed that a change in 1 U of FGF-
21 would be paralleled by a change of 0.09 mg/dL in
TG levels (P = 0.02). In addition, a positive association
was found with AFABP levels, with a change of 1 U
paralleled by a change of 2.5 mg/dL in TG levels
(P = 0.04).
The relevant decreases in TC and LDL cholesterol
levels in transwomen were positively associated with
changes in resistin levels. A decrease of 1 U of resistin
would result in a decrease of 5.2 mg/dL TC (P = 0.004)
and 4.1 mg/dL LDL cholesterol (P = 0.005; Supplement
Table 1). In contrast, an increase in LDL cholesterol in the
transmen was dependent on a decrease in FGF-21 levels
(20.08 mg/dL/Δunit; P , 0.001), an increase in physical
Figure 2. Univariate Spearman correlations of changes in potential predictors and changes in metabolic parameters. Heatmaps of univariate
Spearman correlations of changes in potential predictors (y-axis) and changes in metabolic parameters (x-axis). Colors indicate either positive (red)
or negative (blue) associations. Statistically significant correlations are indicated by black dots. Bold characters indicate statistically significant
differences (P , 0.05) in metabolic parameters from baseline values.
Figure 3. Variables selected as predictors from a LASSO to explain the change in metabolic parameters after treatment. Heatmaps of variables
selected as predictors (y-axis) from a LASSO to explain the change in metabolic parameters (x-axis) after treatment of (Left) female to male or
(Right) male to female. Colors indicate either positive (red) or negative (blue) associations. Gray shades indicate variables not selected. Statistically
significant associations in the final model are indicated by black dots. Bold characters indicate statistically significant differences (P , 0.05) in
metabolic parameters from baseline values.
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activity (10.5 mg/dL/Δunit; P = 0.001), and an increase in
the WHR (1.8 mg/dL/Δ0.01; P = 0.02).
The decrease in the HDL% in the transmen was best
explained by the decrease in adiponectin levels (Fig. 2),
which translated into a decrease of 0.6% per 1000 units
(P = 0.01; Supplement Table 2). In the transwomen, HDL
% did not change significantly, although it was influ-
enced by a variety of independent variables in an inverse
manner, namely resistin (20.7%/Δunit; P = 0.04), fat
mass (20.53%/Δkg; P = 0.005), WHR (20.2%/Δ0.01;
P = 0.02), and age (20.12/y; P = 0.04).
An increase in HDL in the transwomen was dependent
on an inverse association with fat mass (20.64 mg/dL/
Δkg; P = 0.007). No good predictor for the decrease in
HDL in the transmen could be identified.
Glucose metabolism
No relevant, independent predictors for the changes in
HOMA-B, HOMA-IR, HOMA of first-phase insulin
secretion, and Stumvoll MCR in the transwomen were
identified. However, an inverse association was found of
the insulinogenic index with the FGF-21 levels (20.43/
Δunit; P = 0.002) and a positive association was found
of the insulin AUC with the progranulin levels (2378.3/
Δunit; P = 0.04).
In the transmen, a statistically significant decrease in
the HOMA-IR was predicted by a variety of changes in
independent variables. A positive association was found
with age (0.04/y; P, 0.001) and chemerin (0.006/Δunit;
P, 0.001), resistin (0.08/Δunit; P = 0.001), and FGF-21
(0.003/Δunit; P, 0.001) levels and was inversely related
to changes in WHR (20.03/0.01; P = 0.01), physical
activity (20.42/Δunit; P , 0.001), leptin (20.06/Δunit,
P , 0.001), and AFABP (20.06/Δunit; P , 0.001).
Blood pressure
Changes in systolic bloodpressurewere best explained by
changes in resistin levels in the transmen (2.8 mm Hg/unit
decrease in resistin levels; P = 0.04) and changes in adipo-
nectin (3 mm Hg/Δ1000 units; P = 0.005) and chemerin
levels (4 mm Hg/Δunit; P = 0.02) in the transwomen.
Discussion
Effect of GAHT on metabolic cytokine expression
From the findings, it is clear that GAHT resulted in a
complete reversal of the observed sexual dimorphism for
adiponectin and leptin, independent of any changes in
anthropometry. This finding is in accordance with earlier
studies in this population (12) and supported by the fact
that testosterone and estradiol can directly regulate leptin
and adiponectin secretion from adipose tissue samples in
both women and men (19, 20).
In contrast, chemerin, progranulin, and FGF-21 levels
did not differ between the transmen and transwomen at
baseline. Although chemerin and progranulin had de-
creased after GAHT in both sexes, FGF-21 decreased
only in the transwomen. Sexual dimorphism for resistin
remained unaffected by 12 months of treatment, in line
with findings from earlier studies (21) and indicating that
sex steroids do not play a major role in its regulation. In
contrast to previous studies of epidemiological samples
(22), a sex difference was not observed. Furthermore, no
change was seen over time in AFABP levels among our
cohort, indicating that AFABP is not affected byGAHT in
either sex.
All these metabolic cytokines have, in epidemiological
studies, been associated with parameters of the MS (10,
23, 24) and showed several correspondingly relevant
correlations on univariate analysis in our sample and also
could explain the changes in the parameters of the MS.
Lipids
Substantial alterations in lipid profiles were ob-
served in both sexes during treatment. The TC levels
decreased in the transwomen, primarily owing to a
reduction in LDL cholesterol. In contrast, the LDL
cholesterol levels increased in the transmen, resulting
in a decrease in the HDL/TC ratio among the members
of this group. These findings are in accordance with
those from earlier studies (9) and also with the gender
dimorphism reported for lipoproteins in the general
population (25).
The decrease in TGs in transwomen was best
explained by a relative change in fat mass and FGF-21
levels, after accounting for other potential confounders.
The positive association with fat mass is in accordance
with studies showing that the secretion of TG-rich li-
poproteins and their degradation is, among others, de-
termined by lipoprotein lipase (LPL) in adipose tissue
(26). A possible explanation for the negative effect of
FGF-21 on TGs in our lean transwomen might be an
FGF-21-dependent, accelerated lipoprotein catabolism in
adipose tissues, thereby reducing TGs, such as has been
demonstrated in mice (27). In contrast, our data suggest
the opposite associations in our transmen cohort, in
whom, although remaining stable during the observation
period, FGF-21 was positively correlated with changes in
TG levels. Our findings, therefore, might suggest a sex-
dependent mechanism with regard to the metabolic
effects of FGF-21. Larson et al. (28) have recently
demonstrated in a rodent model that FGF-21 regulation
and its metabolic effects are highly dependent on the sex
steroid milieu. Furthermore, sex has been demonstrated
as a major predictor of FGF-21 serum levels in cross-
sectional data (29).
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In addition, a positive association was found for
AFABP levels in the transmen, with a change of 1 U
paralleled by a change of 2.5 mg/dL in TG levels. This is
supported by earlier epidemiological studies that found
an independent positive association of AFABP and TGs
(22, 30), although in one study this was only true for
males (22).
The substantial decrease in TC and LDL cholesterol
levels and the HDL% in the transwomen was positively
associated with changes in resistin levels. This is in line
with previous research demonstrating that resistin might
reduce LDL cholesterol clearance by downregulating the
hepatic LDL receptor, in part via proprotein convertase
subtilisin/kexin type 9 (31). The increase in HDL cho-
lesterol, in contrast, was dependent on a negative asso-
ciation with fat mass, a well-established association, and
might among other mechanisms result from a decrease in
plasma cholesteryl ester transfer protein expression (32).
However, an increase in LDL cholesterol levels in the
transmen was dependent on a decrease in FGF-21 levels
and an increase in physical activity and the WHR. It has
been shown in rodent models that FGF-21 deficiency
results in an increase in hepatic cholesterol biosynthesis
and a shift fromHDL to LDL, potentially again mediated
via the proprotein convertase subtilisin/kexin type 9
pathway (33). The decrease in theHDL/TC ratiowas best
explained by a decrease in adiponectin levels, potentially
mediated by adiponectin’s effects on hepatic LPL activ-
ity (34).
It was not possible to identify an independent pre-
dictor for the decrease in HDL cholesterol in the
transmen, indicating that those changes were directly
attributable to GAHT, in line with earlier reports of the
effects of exogenous androgen administration in hypo-
gonadal men (35) and transmen (6) and, again, poten-
tially mediated via increasing LPL activity.
Blood pressure
Although changes in blood pressure were not sub-
stantial across whole groups, individual changes could be
explained by an inverse association with changes in
resistin levels in the transmen and a positive association
with adiponectin and chemerin levels in the transwomen.
Previous studies have revealed that hypoadiponectinemia
is an independent risk factor for arterial hypertension
(27). However, the role of adiponectin in hypertension is
not yet fully understood. Thus, an association between
adiponectin multimer composition and hypertension has
been suggested by Baumann et al. (36). Chemerin has
been linked to hypertension in epidemiological samples
(37), and preclinical data have indicated that it might be
involved in amplifying sympathetic nerve-mediated ar-
terial contractions (38).
The findings regarding resistin were, however, unex-
pected, because resistin has been linked to promoting
hypertension, possibly via activation of the renin–
angiotensin system (39).
Glucose metabolism
GAHT in the transwomen resulted in an increase in the
markers of insulin resistance, first-phase insulin secretion,
and a decrease in insulin sensitivitymarkers. In contrast, a
substantial decrease in the HOMA-IR was found as a
measure of insulin resistance in the transmen.
Most changes in parameters of glucose metabolism in
the transwomen seemed to be directly attributable to the
reversal in the sex steroid milieu and not via indirect
treatment effects such as metabolic cytokine expression
or changes in body composition.
Fasting glucosemetabolism indexes such as theHOMA-
IR predominately measure hepatic insulin sensitivity, but
dynamic OGTT-based indexes such as the Stumvoll
MCRmeasure both hepatic andmuscle insulin sensitivity
(40). Thus, these findings indicate that GAHT in the
transwomen decreased hepatic and muscle insulin sen-
sitivity, and testosterone treatment in the transmen im-
proved hepatic insulin resistance. These findings are in
accordance with earlier research of transgender indi-
viduals in whom E2 and CPA treatment increased fasting
insulin and decreased glucose usage during a hyper-
insulinemic euglycemic clamp, but the fasting glucose
levels were unaffected (41).
In the transwomen, progranulin levels were positively
associated with insulin AUC during the OGTT, and the
insulinogenic index, as a measure of b-cell function, was
negatively affected by changes in FGF-21. Although it
is quite well-established that progranulin contributes to
insulin resistance (42), a bidirectional link might exist
between FGF-21 and glucose metabolism. Although
FGF-21 has been shown to have protective effects on islet
cell functioning and insulin secretion in chronic hyper-
glycemia in rodents (43), FGF-21 also serves as an in-
dependent predictor of the MS and type 2 diabetes
mellitus in apparently healthy white individuals (44).
Hypothetically, the negative association between FGF-21
and the insulinogenic index could represent a beneficial
metabolic status of insulin sensitivity or, alternatively,
FGF-21 resistance (45).
In the transmen, the substantial decrease in the HOMA-
IR was determined by a variety of changes in body com-
position, metabolic cytokine expression, and behavioral
measures, as indicated by the negative association with
the individual’s physical activity parameters. Although
the positive association of chemerin, resistin, and FGF-21
withHOMA-IR indicate a negative effect of these cytokines
on insulin resistance, the opposite was true for leptin and
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AFABP. Leptin is an adipokine that reverses insulin re-
sistance in metabolic disease states such as lipodystrophy
(46). In contrast to leptin, the negative association of
AFABP with HOMA-IR is counterintuitive, because
AFABP is regarded an insulin resistance-inducing adipo-
kine (47) and AFABP inhibition improves insulin sensi-
tivity (48).
One strength of our research was that the findings were
obtained from a well-defined cohort of transgender indi-
viduals undergoing a standardized protocol, including dy-
namic measures of glucose metabolism, body composition
measurements, and liquid chromatography mass spectrom-
etry sex steroid measurements. It could be argued, perhaps,
regarding the burgeoning number of newly identified met-
abolic cytokines in recent years, that those investigated in our
study represent only an arbitrary selection. However, to the
best of our knowledge, ours is the first study of this type of
population to investigate such parameters comprehensively
concerning the contribution of these metabolic cytokines to
sex steroid-driven metabolic regulation.
Nevertheless, the present study had some limitations
that should be considered. First, the general transferability
of the results to the general population, in terms of the
effects of sex steroids on the outcomes investigated, could
be limited. This is potentially because GAHT, for most
transwomen, includes antiandrogenic co-medication. There-
fore, it might be that some of the observed effects are not
primary attributable to the effects of estradiol and/or
androgen withdrawal but instead to the intrinsic effects
of CPA. We could not exclude that the different routes of
application of estradiol in the transwomen might have
had an effect on the outcomes we investigated. Because
the type of estradiol used was dependent on the age of the
transwomen, we did not separately control for estradiol
type. According to the published data, the dosages used in
our study are comparable regarding overall E2 exposure
(49). We also did not observe any relevant differences
regarding serum steroid levels or FSH and LH as sur-
rogate markers for adequate hormone substitution be-
tween the two groups (Supplemental Table 7).
Additionally, the cycle phase in the transmen group
was not controlled, which might have further compro-
mised the detection of clear hormonal effects. Future
studies using larger samples should account for such
differences. Finally, because the 2 groups were of unequal
size (i.e.,more transmen than transwomen), we could not
rule out that we missed some treatment effects in the
smaller group owing to missing power.
Conclusions
One of the most in-depth analyses to date has, in our
study, succeeded in further disentangling the direct and
indirect effects of GAHT on the components of theMS in
transgender individuals. Many effects of GAHT on the
components of the MS seem to be directly attributable to
changes in the sex steroidmilieu. However, we also found
indirect sex-specific effects involving mediators such as
changes in body composition and metabolic cytokine
secretion, or a combination of both of these factors.
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